Kailera Therapeutics, Inc. KLRA
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on developing a diversified pipeline of GLP-1 therapies for obesity treatment. Headquartered in Waltham, Massachusetts, the company advances multiple clinical programs including ribupatide, its lead product candidate that functions as a on…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees145
TickerKLRA
Statistics
Market Cap$2.32B
Revenue (TTM)$0
Net Income-$149.0M
Net Margin—
EPS$-1.26
P/E-15.53
P/S—
P/B-5.35
EV/EBITDA-15.07
ROE-36.9%
Dividend Yield—
Price$19.70
Data: Twelve Data · Revenue = mcap / P/S